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7-O-succinyl macrolactin A has shown anti-inflammatory, anti-
angiogenesis, and anti-metastatic effects. It also exhibits strong 
suppression of tumor growth. In our previous study, we assessed 
the anti-neoplastic effects of 7-O-succinyl macrolactin A 
tromethamine salt (SMA salt) on a glioma cell line. Moreover, 
according to our data, SMA salt might be contributed to the 
inhibitory effects on migration and invasion, as well as a cytotoxic 
effect on the glioblastoma cell lines. In the present study, we 
investigated the anti-tumor effects of combination therapy with 
SMA salt and temozolomide (TMZ) in glioblastoma cell lines. The 
combination therapy affected cell viability significantly, decreasing 
in glioblastoma cell lines. In cell migration assays, combination 
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therapy showed more inhibitory effects than TMZ in these cell lines. 
The tumor volume was significantly decreased in the combination 
group compared with both TMZ and control groups by using the 
orthotopic mouse model. The effects of combination therapy with 
SMA salt and TMZ attributed to the inhibition of migration, invasion 
activities and anti-tumor effects. SMA salt could be one of the 
promising candidates for combination therapy in clinical settings. 
Keywords: glioblastoma, combination therapy, temozolomide, 7-O-
succinyl macrolactin A tromethamine salt.
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Glioblastoma (GBM) is the most frequent primary malignant brain 
tumor in adults [1, 2]. Although GBM patients receive aggressive 
multi-disciplinary treatments such as surgery, radiation, and 
chemotherapy, their median survival is less than 15 months [3-8]. 
In 2005, Stupp et al. reported that median survival was longer in the 
radiation plus temozolomide (TMZ) group than the radiation only 
group. Many researchers were concerned about the effect of TMZ 
on GBM patients or combination effects with other drugs. Therefore, 
numerous articles were published associated with TMZ.
TMZ is a well-known alkylating agent and is applied widely with 
GBM as a first-line treatment [9-11]. TMZ is rapidly absorbed 
with almost 100% bioavailability by oral administration [12, 13]. It 
crosses the blood-brain barrier and achieves effective 
concentrations in the CNS, approximately 30% to 40%. However, 
treated with highly anticipated TMZ, most GBM patients still die 
within 2 years. It is important to find a new regimen to prolong the 
survival of GBM patients. 
In recent years, the anti-angiogenic agent has gained popularity 
from researchers and physicians. Some groups worked on anti-
angiogenic agents, such as cilengitide or bevacizumab [14-17]. 
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However, these papers did not produce desirable results. In a 
randomized phase 3 study with bevacizumab, the progression-free 
survival was longer in the bevacizumab group (10.6 months) than in 
the placebo group (6.2 months), whereas the overall survival was 
similar in both the bevacizumab and placebo groups (16.7 months) 
[14]. In another multicenter, randomized, phase 3 study, there was 
no significant difference in overall survival between the control 
group (26.3 months) and the cilengitide group (26.3 months) [15]. 
This study only included O6-alkylguanine DNA alkyltransferase 
(MGMT) promoter methylated patients, thus the overall survival 
was longer than other studies. 
7-O-succinyl macrolactin A (SMA) and macrolactin A (MA) are 
macrolactins generated from Bacillus polyfermenticus KJS-2 [18]. 
Macrolactins are macrolides containing three separate diene 
structure elements in a 24-membered lactone ring [19]. 
Macrolactins were first described in 1989 by Gustafson et al. and 
were reported to have antiviral properties, with MA being the most 
active compound of the group [19]. Then, SMA was found in 2000 
by Jaruchoktaweechai et al. [20], and Romero-Tabarez et al. also 
described the inhibition of vancomycin-resistant enterococci in 
2006 [21]. According to reports, SMA has shown anti-angiogenic
and anti-metastatic effects [22, 23]. In our previous study, we 
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assessed the anti-neoplastic effects of 7-O-succinyl macrolactin 
A tromethamine salt (SMA salt) on GBM. Moreover, SMA salt might 
attribute to the inhibitory effects on migration and invasion, as well 
as cytotoxic effects on glioma cell lines [24].
In the present study, we investigated the anti-tumor effects of 




The U87MG, U251MG, and LN229 cell lines were human glioma cell 
lines purchased from American Type Culture Collection (ATCC, 
Manassas, VA, USA). Cells were cultured in complete Dulbecco’s 
Modified Eagle Medium (DMEM), which was supplemented with 10% 
fetal bovine serum (FBS) and incubated at 37˚C and 5% CO2.
Cell viability assay 
The cytotoxicity of SMA salt (Daewoo Pharmaceutical Company, 
Seoul, Korea), TMZ and a combination of SMA salt and TMZ was 
measured using the Cell Counting Kit-8 (CCK-8; Dojindo 
Molecular Technologies Inc., Tokyo, Japan). Each cell line was 
seeded into 96-well plates at a density of 5 x 103 cells per well to 
allow for overnight adhesion. The next day, the cells were treated 
with SMA salt at a concentration of 25 and 50 µM and TMZ at a 
concentration of 500 µM. After 2 days, we added 10 μL of the 
CCK-8 solution per well and then incubated for 2 hrs at 37˚C and 
5% CO2. The optical density (OD) of the sample plate was 
measured at 450 nm by an ELISA reader (VERSAmax microplate 
reader, Molecular Device, CA, USA). 
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Cell migration assay
The insert of a 24-well Transwell apparatus (Corning, Corning, NY) 
was incubated at 37˚C for 1-2 hrs. The U87MG, U251MG and 
LN229 cells (2 x 105 cells/mL) were treated with SMA salt, TMZ, 
and the combination of SMA salt and TMZ, and cultured for 24 hrs 
with serum-free medium. FBS-containing medium was added to 
the lower chamber and harvested proper number of cell was added 
to the insert. After 24 hrs, cells that were remaining in the insert 
(i.e., non-invading cells) were gently retrieved using a cotton-
tipped swab and allowed to air dry for 20 min. A solution of 0.4% 
crystal violet (500 μL) was added to each well of the apparatus. 
After 10 min, the migrated cells that traversed the membrane 
separating the insert from the lower chamber were stained by 
dipping the lower surface of the membrane into the stain. The 
stained membranes were washed several times with water and 
allowed to air dry. The results of cell migration assays are
described as a percentage (count in the lower chamber as % of total 
cell count).
Cell invasion assay
Matrigel (BD, Franklin Lakes, NJ) was thawed overnight at 4 ng and 
diluted (1-5 mg/mL) in serum-free cold DMEM. A 100 μL volume 
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of the diluted Matrigel was added to the upper chamber of a 
Transwell apparatus and incubated at 37˚C for 4-5 hrs to allow 
the gel to swell. The treated U87MG, U251MG and LN229 cells (2 
x 105 cells/mL, 24 hrs) were prepared in serum-free medium, and 
proper number of cells was harvested and added to each insert. 
Medium containing FBS was added to the lower chamber of the 
Transwell apparatus. After 24 hrs, non-invading cells were 
removed, and the invading cells were quantified as described above 
[29]. 
Orthotopic mouse model
Six-week-old Female Balb/c-nu mice were ordered from Orient 
Bio (Seongnam-si, Korea; distributor for Charles River, Wilmington, 
MA). Thirty mice were used for tumor volume and survival analysis. 
Each experiment utilized 15 mice. Fifteen mice were divided into 3 
groups in each experiment. All of them were anesthetized and the 
head was fixed in a stereotactic frame, followed by the creation of a 
midline scalp incision (1 cm). A small hole was made 0.5 mm 
anterior and 2 mm lateral from the bregma. A sterile 10 μL 
Hamilton syringe with a #26S needle was inserted at a depth of 3.5 
mm from the surface of the skull and withdrawn by 0.5 mm to inject 
2 x 105 U87MG cells in a volume of 2 μL. The injection rate was 
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0.5 mL/min. After the implantation of the tumor cells, the needle 
was kept in place for 3 min to prevent cell reflux. Then, the needle 
was completely withdrawn from the brain over the course of 3 min 
(1.0 mm/min). Finally, the hole was sealed and the skin was sutured. 
All of these steps were followed in our lab protocol. This study was 
approved by the Institutional Animal Care and Use Committee of the 
Medical Science Research Institute, Seoul National University 
Bundang Hospital (authorization number: BA1411-164/058-01).
Treatment protocol and survival analysis
The orthotopic mice were randomly divided into three groups: 
control group, TMZ group and combination group (SMA salt and 
TMZ). We already had performed the SMA salt group in our 
previous study. Therefore, we did not add the SMA salt group in 
this study. The mice in the control group were injected with saline 
only, and both SMA salt and TMZ were administered respectively at 
a dose of 50 mg/kg daily intraperitoneally in the TMZ and 
combination groups. The drug treatments began 7 days after the 
implantation of tumor cells and for 5 days per week. Half of the 
mice were sacrificed 5 weeks after the implantation of the tumor 
cells for tumor volume analysis; the remaining mice were observed 
for another 3 months to analyze survival. Death was defined as a 
8
weight reduction to 75% of their initial weight or an unexpected 
sudden death before that weight was reached.
Evaluation of tumor growth
When we obtained mice brains, the mice were perfused with 
phosphate-buffered saline (PBS) and then fixed in 4% 
paraformaldehyde; after that, the brain was removed for paraffin 
embedding. The fixed brains were coronally sectioned into slices of 
5 μm thickness. The slices were mounted and stained with 
hematoxylin and eosin. The maximal length (L), width (W) and 
height (H) of each tumor sample was measured and used the 
following formula to calculate the tumor volume [30].
Statistical analysis 
We used Student’s t-test analysis for the statistical analysis of 
our data. The Kaplan–Meier method was used for the survival 
analysis. Differences in survival were tested for significance using 




GBM cell line sensitivities to SMA salt and TMZ 
We assessed the effects of combination therapy on GBM cell lines 
for 48 hrs. In the U87 cell line, the viability of the combination 
group (39.9%) was significantly lower than other two groups (TMZ 
group, 58%; SMA salt group, 62.8%) at the concentration of SMA 
salt at 25 µM (P < 0.001 and P <0.0001). In U251 and LN229 cell 
lines, the combination groups (46% and 40.3%) also showed 
significantly lower cell viability than the TMZ group (56.5%, P < 
0.05 and 46.1%, P < 0.05) and SMA salt group (88.4%, P < 0.001 
and 59.9%, P < 0.0001) at a 25 µM concentration of SMA salt (Fig. 
1A, 1B, and 1C). Moreover, at the 50 µM concentration of SMA salt, 
the cell viability of each cell line was similar to the 25 µM 
concentration of SMA salt (Fig. 1D, 1E, and 1F). We found that 
there was no significant change when the concentration of SMA salt 
was doubled in the U251 cell line. However, in the other two cell 
lines, a doubled concentration of SMA salt resulted in approximately 
half the decrease in cell viability. 
The effects of SMA salt and TMZ on migration and invasion 
We performed the cell migration assay with the 24-well Transwell 
apparatus and followed the manufacturer’s protocol. Eventually, the 
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stained migrating cells were counted to assess the effects of SMA 
salt and TMZ. The cell migration abilities in U87 cell lines were 
significantly decreased in the combination group (12.2%) than in 
the SMA salt (25.03% and P < 0.001) and TMZ groups (44.01% and 
P < 0.001) (Fig. 2A). Similar results were found in the LN229 cell 
line. There was a significant difference among the combination 
group (35.1%), SMA salt group (60.49% and P < 0.001) and TMZ 
group (63.72% and P < 0.001) (Fig. 2C). Moreover, the inhibitory 
effect of migration on the U251 cell line was significantly higher in 
the combination group (8.17%) than in the TMZ group (42.38% and 
P < 0.001) and SMA salt group (67.9% and P < 0.001) (Fig. 2B). 
However, The U251 cell line showed a different pattern with U87 
and LN229 cell lines. 
We also evaluated the inhibitory effect of invasion in three cell 
lines, U87, U251, and LN229. The combination group showed 
greater inhibitory effects than the SMA salt and TMZ groups on cell 
invasion in the three cell lines (Fig. 2D, 2E, and 2F). In the U87 cell 
line, the combination group (28.45%) showed greater inhibitory 
effects when compared with the SMA salt group (53.99% and P < 
0.01) or TMZ group (67.24% and P < 0.001). In the U251 cell line, 
there was a significant difference in the combination group (36.55%) 
compared with the SMA salt (68.45% and P < 0.01) or TMZ groups 
11
(55% and P < 0.05). Similar results were also shown in the LN229 
cell line. The combination group (25.26%) showed a significant 
difference not only in the SMA salt group (48.13% and P < 0.001) 
but also in the TMZ group (42.01% and P < 0.01). Interestingly, the 
U87 cell line showed results in both the cell migration assay and 
invasion assay. Moreover, the same situation was observed in the 
other two cell lines.
The effects of SMA salt and TMZ on tumor volume and survival 
analysis
The inhibitory effects on tumor growth were evaluated by tumor 
volume assessment. To mimic the clinical situation, mice grew 
tumors for 1 week. After 1 week of the stationary phase, they were 
administered treatment for 4 weeks with proper drugs, including 
TMZ or SMA salt. We obtained the mean tumor volume from each 
group. The mean tumor volume in the combination group (2.6 ± 1.7 
mm3) was significantly smaller than in the TMZ group (5.1 ± 1.9 
mm3, P < 0.05) and the control group (7.8 ± 1.1 mm3, P < 0.01) (Fig. 
3). 
The data in Fig. 4 includes the survival analysis on the orthotopic 
mouse model. The mice were divided into three groups: a control 
group, TMZ group, and combination (TMZ and SMA salt) group. 
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The mean survival period of the control, TMZ, and combination 
groups was 53 days, 130 days, and 130 days, respectively. The 
overall survival in the TMZ group was significantly higher than in 
the control group (P = 0.004). In addition, overall survival in the 
combination group was also significantly higher than in the control 
group (P = 0.004). However, the data showed that there was no 




SMA and MA are macrolactins generated by Bacillus 
polyfermenticus KJS-2 [18]. Both are well known as antibacterial 
substances [18, 25]. According to other research, SMA has better 
antibacterial activity and less cytotoxicity than MA [26]. SMA has 
also shown other effects such as anti-inflammatory, anti-
angiogenesis and anti-metastatic effects [22, 23, 26]. Moreover, 
Sushil C. Regmi et al. used colon and lung cancer xenograft models 
to prove the anti-tumor effect and suggested that SMA could 
function as a potential monotherapy or in combination with the 
cytotoxic chemotherapeutic drugs [27]. In our previous study, we 
assessed the anti-neoplastic effects of SMA salt on GBM cell lines 
[24]. Moreover, according to our data, SMA salt might attribute to 
the inhibitory effects on migration and invasion and had cytotoxic 
effects on the GBM cell lines. Ultimately, we suggest SMA salt as a 
monotherapy with anti-tumor activity in a glioma orthotopic mouse 
model.
In the present study, we focused on investigating the anti-tumor 
effects of combination therapy with SMA salt and TMZ in GBM cell 
lines. In this study, we used previous experience to assess the 
combination therapy with SMA salt and TMZ. The data showed that 
the GBM cell viability, which was used in this study, was lower in 
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the combination therapy than in the TMZ group. We also found the 
same situation in the migration assay and invasion assay. There 
was an interesting finding that U87 and LN229 cell lines were more 
sensitive than the U251 cell line when treated with a doubled 
concentration of SMA salt. From the in vitro data, we suggest that 
combination therapy with SMA salt and TMZ may attribute to the 
anti-tumor effect on the GBM cell lines. 
The orthotopic mouse model was used to evaluate the effect of 
combination therapy with SMA salt and TMZ. The implanted tumor 
volume that was obtained from each orthotopic mouse was 
calculated to compare the mean tumor volume of three groups. The 
mean tumor volume in the combination group was lower than in the 
TMZ group and control group. 
Four-month-survival analysis was carried out simultaneously with 
mean tumor volume evaluation. In this experiment, the overall 
survival in the combination and TMZ groups was longer than in the 
control group, respectively (P = 0.004, and P = 0.004). However, 
there was no significant difference between the combination group 
and TMZ group. We assumed that the main reason there was no 
difference between the two groups was due to the blood-brain 
barrier (BBB) and time. SMA salt may or may not cross the BBB. 
To discover this, we would like to do more research on the BBB and 
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SMA salt. Furthermore, we should prolong the period of survival 
analysis to observe the difference between the temozolomide group 
and the combination group. Overall, the in vivo experiment data 
indirectly demonstrated the effect of combination therapy in the 
orthotopic mouse model with the U87 cell line. 
  Another strong effect of SMA was anti-angiogenesis. Anti-
angiogenesis was explored in publications by Judah Folkman in the 
1970s, which is an interesting issue for those researching tumors. 
According to some reports, SMA exhibited stronger anti-
angiogenic activity than MA and showed suppression of tumor 
growth and tumor-induced angiogenesis in an MDA-MB-231 
human breast cancer cell-inoculated CAM assay [22]. The main 
mechanism of this study was that SMA and MA mediated the 
inhibition of class I PI3K activity and signaling to inhibit the 
angiogenic effect. 
  Recently, many papers on chemotherapy treatment, especially 
anti-angiogenesis, were published [11, 14-16, 28]. The main 
targets of these papers were cilengitide (an anti-angiogenic 
inhibitor of integrins, αvβ3 and αvβ5) and bevacizumab (an anti-
angiogenic inhibitor of vascular endothelial growth factor A). For 
instance, cilengitide was used in combination therapy with belotecan 
against glioblastoma [11]. The authors used immunohistochemistry 
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to confirm the anti-angiogenic effect with CD 31, a marker of 
endothelial cells and tumor angiogenesis and used in vitro and in 
vivo experiments to confirm anti-tumor effects and combination 
therapy with cilengitide and belotecan to prolong the survival of 
mice. These results showed a favorable expectation for the 
treatment of glioblastoma. In a multicenter randomized open-label 
phase 3 trial for cilengitide combined with standard treatment, 
however, they demonstrated dismal results [15]. Patients did not 
gain any benefits from cilengitide, the median overall survival in the 
control group was the same as the cilengitide group. The results of 
clinical trials were not as good as the laboratory data, in reality. 
The results of SMA salt from the lab experiments were attractive 
for researching GBM treatment. Therefore, the variable effects of 
SMA salt on GBM cell lines should be validated with GBM patients 
in the further clinical studies.
In conclusion, this study has shown the feasibility of combination 
therapy on GBM cell lines in vitro and in vivo. Although the effect of 
combination therapy in survival analysis is not as satisfactory as 
our previous study, we might suggest that the effects of 
combination therapy with SMA salt and TMZ attributed to the 
inhibition of migration and invasion activities and anti-tumor effects 
on GBM cell lines. SMA salt could be one of the promising 
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candidates for combination therapy in clinical settings. The exact 
mechanisms of combination therapy of TMZ and SMA salt in GBM 
cell lines will need more examination in future studies.
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The anti-tumor effect on the viability in the different cell lines.
Three cell lines were seeded in 96-well-plates and treated with 
SMA salt only, TMZ only, and combination therapy. Cells were 
treated both 25 μM (A, B, and C) and 50 μM (D, E, and F) 




Cell migration and invasion assay on U87, U251, and LN229 cell lines. 
The 25 μM concentration of SMA salt was been chose to perform 
the cell migration (A, B, and C) and invasion (D, E, and F) assay 
with Transwell apparatus. The scale bar on the image was 35.29 μm. 
* P < 0.05, ** P < 0.01, and *** P < 0.001.
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Figure 3.
The change of tumor volume rests upon treatment with temozolomide 
only, and combination therapy. The mean tumor volume of 
combination treatment group was significantly lower than the 
control group (** P < 0.01) and temozolomide only treatment group 
(* P < 0.05). The scale bar on the image was 1000 μm.
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Figure 4.
Survival of glioma xenograft mouse model. Most of the control group 
mice (blue line) died nearly in 40 days. However, rest of groups 
mice (green and yellow lines, two lines were overlapped) were 
lived to the end of the experiment. There was no difference 
between the temozolomide and combination treatment group. 
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                           국문 초록
교모세포종에 대한 7-O-succinyl 
macrolactin A tromethamine 염과
테모졸로미드 병합치료의 효과
7-O-succinyl macrolactin A 는 염증억제작용, 혈관생성억제작용, 
전이억제작용을 하고 있다고 알려졌다. 더불어 종양생성억제작용도
있다고 밝혀졌다. 이전 연구에서 7-O-succinyl macrolactin A 
tromethamine 염(SMA 염)가 교모세포주에 대한 종양생성억제작용이
있음을 규명한 바 있다. 이 연구 결과에 따르면 SMA 염은
교모세포주에서 세포이주, 세포침입을 억제하는 작용을 하고
교모세포주에 대한 세포독성도 보여주었다. 본 연구는 SMA 염과
테모졸로미드의 병합치료가 교모세포주에 항암효과가 있는지를
알아보고자 실험을 진행하였다. 병합치료 결과, 교모세포주의 세포
활성도를 많이 감소 시켰다. 세포 이주 실험에서 병합 치료군이
테모졸로미드 단독 치료군 보다 세포 이주 억제 작용이 더욱 컸다. 
마우스 동물 모델을 통하여 병합 치료군이 테모졸로미드 단독 치료군
보다 종양의 부피가 유의하게 줄어든 것을 볼 수 있다. SMA 염과
테모졸로미드의 병합치료 방법은 세포 이주와 세포 침입의 억제 작용이
있고 또 항암작용을 보여 주었다. 
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이 결과를 토대로 SMA 염은 임상에서 병합치료로 쓸 수 있는 또
하나의 희망적인 후보약물이 될 것으로 기대된다.
주요어:  교모세포종, 병합치료, 테모졸로미드. 7-O-succinyl
macrolactin A tromethamine 염.
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